Single or Double Site Cannulation for Veno-Venous Ecmo in Severe Obese Patient?

Angela Lappa MD\(^a\), Marzia Cottini MD\(^b\), Silvia Donfrancesco, MD\(^a\), Federico Ranocchi MD\(^b\), Giampaolo Luzi MD\(^b\), Andrea Montalto MD\(^b\), Carlo Contento CCP\(^b\), Agrò Bruno CCP\(^b\), Patrizia Pisani CCP\(^b\), Proietti Antonio CCP\(^b\), Vitalini Emiliano CCP\(^b\), De Marco Marina CCP\(^b\), Petraforte Laura CCP\(^b\), Iaiza Alessandra CCP\(^b\), Antonio Menichetti, MD\(^a\), Francesco Musumeci, MD, FECTS\(^b\)

\(^{a}\)Department of Heart and Vessels, Cardiovascular Intensive Care Unit, “S. Camillo-Forlanini” Hospital, Rome, Italy
\(^{b}\)Department of Heart and Vessels, Cardiac Surgery Unit and Heart Transplantation Center, “S. Camillo-Forlanini” Hospital, Rome, Italy
marzia.cottini@hotmail.it

Abstract: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is an extracorporeal respiratory support used as therapeutic option in patients affected by severe acute respiratory distress syndrome (ARDS), who are not responding to other medical or mechanical treatment.

By providing supplementation of pulmonary gas exchange, VV-ECMO allows the lungs to rest and avoids the use of aggressive mechanical ventilation. Therefore, this support provides the basis for a possible recovery of the pulmonary parenchyma damaged by the underlying respiratory disease. Over the last two years, there has been a widespread increase in the use of the VV-ECMO due to the influenza A-H1N1 pandemic. The VV-ECMO approach could be with single or double site cannulation: the single one is performed to reduce the incidence of bleeding, infection and get better the medical and nursing management of the patient (prone position, mobilization, and so on) but this cannulation is a challenge for the mechanical support because of higher resistances, more shunts, much more modification of the flux with a little bit dislocation (for instance during transfer).

We reported a case of the first experience of unsuccessful use of single cannulation with VV-ECMO, thus requiring a conversion to dual cannulation with a successful outcome.

Keywords: Acute respiratory distress syndrome (ARDS); ECMO (extracorporeal membrane oxygenation); hypoxia; lung pathology; lung infection.

Abbreviations: VV-ECMO-Veno-venous Extracorporeal Membrane Oxygenation, ARDS- Acute Respiratory Distress Syndrome, BMI-Body Mass Index, CT-Computed Tomography, ABG-Arterial blood gases, WBC-White Blood Count, CRP-C-Reactive Protein, TEE-Transesophageal Echocardiographic, APTT-Activated Partial Thromboplastin Time, SIMV-Synchronized,Intermittent Mandatory Ventilation, PS-Pressure Support, PEEP-Positive end-expiratory pressure, RR-Respiratory Rate

1. MAIN BODY TEXT

A 49-year-old male affected by severe obesity (BMI 40.1 Kg/m\(^2\)), sleep apnea syndrome and type II diabetes mellitus, developed severe ARDS by influenza A, which was not responsive to maximal ventilatory support and to cycles of prone positioning in a secondary hospital. After 48 hours, the patient was recovered to our Cardiovascular Intensive Care Unit to perform VV-ECMO treatment.

Upon admission, the chest Computed Tomography (CT) scan showed an extensive case of ARDS with pulmonary infiltrates affecting all lung fields (Figure 1). The Murray Score (1) was 3.5 and arterial blood gases (ABG) showed: pH 7.33, pO\(_2\) 40 mmHg, pCO\(_2\) 51 mmHg, HCO\(_3\) 25 mmol/L, pO\(_2\)/FiO\(_2\) ratio 172 and evidence of mild tissue hypoxia (Lactate 3.4, SVO2 74,7, Table 1). Laboratory values revealed white blood count (WBC) 4.420 × 10\(^9\)/l, C-Reactive Protein (CRP) 8.45 mg/dl, the cultural samples were collected and both the tracheal aspirate and the nasal swab tested were positive to Influenza A (not type H1N1). The patient had no other sign of systemic failure (PA 165/50 mmHg, HR 95 beats/min, diuresis 70 ml/h).
Table1. Murray Score Calculator for the according to the Conventional Ventilation or ECMO for severe Adult Respiratory Failure (CESAR trial, Peek et al, Lancet 2009)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO2/FiO2 in mmHg on 100% oxygen for at least 20 minutes</td>
<td>172</td>
</tr>
<tr>
<td>Number of quadrants with infiltration seen on chest x-ray</td>
<td>4</td>
</tr>
<tr>
<td>PEEP value on the ventilator</td>
<td>15</td>
</tr>
<tr>
<td>Compliance (ml/cmH2O) [Compliance may be calculated as: (Tidal Volume) / (PIP-PEEP)]</td>
<td>45</td>
</tr>
<tr>
<td>SVO2 (%)</td>
<td>74.7</td>
</tr>
</tbody>
</table>

Figure1. Computed tomography, short-axis view of lung effusion and acute respiratory distress syndrome at the control after the transfer from secondary hospital

Figure2. Chest X ray control of single cannulae VV-ECMO implantation.

Due to the cultural results, an antiviral therapy was administered consisting in oseltamivir (orally) and zanamivir (via aerosolization) for ten days, in addition to the piperacillin-tazobactam and clarithromycine (empirical therapy started in the suspicious of community-acquired pneumonia). Methylprednisolone was administered at the dosage of 1mg/Kg bolus, followed by continuous infusion of 1 mg/Kg/day in order to induce down-regulation of systemic inflammation, improve pulmonary and extrapulmonary organ dysfunction (2). No muscle relaxants were administered.

VV-ECMO was set-up using single cannulation with an Avalon Elite Bicaval Dual Lumen Catheter 31Fr (Avalon laboratories, LLC 2610 E. Homestead Place Rancho Dominguez, CA 90220,USA) percutaneously positioned in the right internal jugular vein and connected to an ECMO circuit (Maquet® Cardiopulmonary AG Hechinger Strabe 38 72145 Hirrlingen, Germany). Using transeosophageal echocardiographic (TEE), the cannula was placed and documented into the inferior vena cava with the outflow orifice pointed 280° towards the tricuspid valve (Figure 3). The correct positioning of the cannula was also confirmed by a chest X-ray. The ECMO flow rate was 51.4
Single or Double Site Cannulation for Veno-Venous ECMO in Severe Obese Patient?

ml·Kg⁻¹·min⁻¹ (set up on Height 180 cm and weight 130 Kg), air flow 8 l/min and FiO₂ 0.9. The perfusionists checked pressure drop and gas exchanges of the oxygenator every 12 hours. The Gases after VV-ECMO were get better (pH 7.41, PCO₂ 35.3, PO₂ 41.4, SVO₂ 73.3, Hb 11.8).

Anticoagulation was managed with continuous infusion of heparin in order to maintain aPTT (activated partial thromboplastin time) value at approximately 60 seconds, with a laboratory check conducted every 8 hours.

Synchronized intermittent mandatory ventilation (SIMV) was employed with the following setting: tidal volume 6ml/Kg, PS 22 cmH₂O, PEEP (Positive end-expiratory pressure) 12cmH₂O, RR (respiratory rate) 10/min, FiO₂ 0.6.

Three unexpected episodes of decreased pump flow rate occurred 48 hours after VV-ECMO implantation. Each time, the arterial blood gas values worsened significantly, with the following mean values: pH 7.48, pCO₂ 31.4 mmHg, pO₂ 41.7 mmHg, even if the oxygenator performance appeared normal. A TEE was performed each time to control cannulae good setting but it showed a displacement of the cannulae, which required repositioning.

Considering the severity of the patient’s clinical status, the estimated long recovery time of the lungs, and the unstable flow of blood due to frequent dislocation episodes of the Avalon cannulae, a double venous cannulation was set-up.

On the 5th day, a new Medtronic 21Fr (Minneapolis MN) cannulae was positioned in the right femoral vein. Under TEE guidance, the pre-existing Avalon Elite DLC was pulled back from the inferior vena cava until the right atrium to avoid recirculation.

With the conversion from single to dual cannulation, the venous blood was drawn from the inferior vena cava through the new femoral cannulae and oxygenated blood returned to the right atrium through the pre-existing Avalon Elite DLC (Figure 4).

Figure 3. Image of single cannulae VV-ECMO, the site of insertion is highlighted by grey arrow.

Figure 4. Switch from single to double venous cannulation with a Medtronic 21Fr (Minneapolis MN) cannula into the right femoral vein (lower grey arrow) and Avalon Elite DLC pulling back from the inferior vena cava until the right atrium (upper grey arrow). The console (yellow star) and oxygenator (yellow asterisk) of ECMO was on the right of patient.
With the conversion from single to dual cannulation, the venous blood was drawn from the inferior vena cava through the new femoral cannula and oxygenated blood returned to the right atrium through the pre-existing Avalon Elite DLC.

Two weeks after the dual cannulation of VV-ECMO, a chest X-ray revealed significant improvement (Figure 5). Gradual weaning from ECMO support was started during the third week. The tracheostomy was not performed in order to decrease bleeding, infection and cruel maneuver in complex patient.

Figure 5. Chest X ray after VV-ECMO cannulae removing

Antiviral therapy was suspended 10 days later, after sterilization of the nasal swab and tracheal aspirate.

ECMO support lasted 21 days, at which time the patient’s ABG evidenced satisfactory values: pH 7.41, pO₂ 135 mmHg, pCO₂ 34 mmHg with minimal ECMO support: FiO₂ 0.21, Air 0.5 lt/min and blood flow 2 L/min. The blood gas at outflow from the oxygenator was pH 7.37, pO₂ 36 mmHg, pCO₂ 38 mmHg. The ventilator support was SIMV, RR9/min, PEEP 10cmH₂O, PS 20cmH₂O, and ECMO was removed.

The patient was extubated after 7 days and underwent non-invasive ventilation cycles, three times a day, until his complete mobilization. He was then transferred to a postoperative rehabilitation clinic in a good condition (Figure 6a and b).

Figure 6. a) Control Chest X ray and b) Control Computed tomography, short-axis documented the resolution of ARDS and lung effusion at the discharge. The patient was transferred to rehabilitation and did not required oxygen treatment.

2. DISCUSSION

VV-ECMO is a valid support for severe and refractory respiratory failure as a bridge to lung transplant or pulmonary recovery. Historically, VV-ECMO has been performed with dual peripheral cannulation, usually inserted into jugular and femoral veins.

For many years VV-ECMO has been used in children through single cannulation in the right internal jugular vein. The catheter has two lumens: one lumen draws blood from both the inferior and the superior vena cava, while the oxygenated blood flows through the second lumen into the right atrium.
In 2009, the U.S. Food and Drug Administration approved the Avalon Elite Bicaval Dual Lumen Catheter to perform VV-ECMO with single cannulation in adult patients. This cannulae is characterized by two lumens, separated by a flexible membrane that divides the oxygenated blood from venous drainage. The distal opening should be placed into the inferior vena cava, while the proximal tip should be in the right atrium facing the tricuspid valve. The correct positioning should be verified through fluoroscopy, transthoracic echocardiogram or TEE which is strongly recommended (3, 4, 5).

Compared to dual cannulation, the advantages of single site cannulation consist in a reduction of cannulae-site infection risk and time-consuming nursing care. Because of the reduction of “plastic” surface in contact with blood, a decrease in the activation of inflammatory cascade is also observed. An additional advantage is the possibility to mobilize the patient, enabling him to participate in physical therapy when required.

In our experience, the most significant complication which can occur is the single cannula displacement, which should be suspected in the presence of acute patient oxygen desaturation, despite proper functioning of the ECMO oxygenator. In this reported case, the minimal movement of patient in daily manoeuvres caused a little bit modification in resistance and flow even if we made secure the cannula. This could be due to the contact of tricuspid valve. During the first four days of VV-ECMO support, three episodes of cannulae displacements occurred. A malrotation of the proximal tip, which was not facing the tricuspid valve, was observed by TEE in all three episodes. It should be highlighted that the dual lumen catheter was secured to the skin with several sutures and a bandage around the forehead which fixed the cannulae to the right side of the face.

In one case, the malrotation occurred after a coughing fit, whilst in two cases it occurred after patient mobilization, despite nursing manoeuvres were performed by a dedicated team, including perfusionist specialists who helped in monitoring and handling catheter and ECMO tubing. The cannula was always repositioned by using ultrasound guidance.

Some cases of single cannulation with Avalon Elite DLC for obese patients are reported in literature, but with lower BMI (about 30 kg/m²) and for a shorter ECMO support period; in fact the median duration described is between 9 and 11 days (3, 4). In our experience, the patient had greater BMI (40.1 Kg/m²) and the VV-ECMO was performed for 21 days and in addition our patient confirmed that the obesity decreases the sensitivity of peripheral tissues to leptin signals and can compromise the immune system as reported in literature (6, 7, 8).

3. Conclusion

According to our experience, the Avalon Elite DLC offers many advantages for Veno-venous extracorporeal membrane oxygenation support in patients affected by severe acute respiratory distress syndrome, who are not responding to other medical or mechanical treatment. In particular, in severe obese patient (BMI more than 35 Kg/m²), the performing of VV-ECMO with single cannulation needs a daily control of cannulae position (we recommend transthoracic echocardiogram or chest X-rays) and a gently management of patient to reduce the dislocation of the cannulae.

**Human rights statements and informed consent:** All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later revisions. Informed consent was obtained from the patient for being included in the image report.

**REFERENCES**


